You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The precision medicine company also is accelerating its push into diabetes, depression, and cardiology after getting its solid-tumor test turnaround down to 9 days.
Now valued at $5 billion, the company will apply the new funding to continue its expansion in diabetes, depression, and cardiology.
In a new study, using larger numbers of patient-specific mutations helped better detect residual disease in breast cancer patients' blood after treatment.
Genes influencing NOTCH pathway activity were linked to head and neck squamous cell carcinoma with a mouse screen centered on genes with long tail mutations in human cases.
The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.
The firm reported quarterly revenues of $8.4 million and large increases in the number of billable tests delivered in the quarter and over the full year.
The funding, part of a larger initiative by Genome Canada, will support two studies in British Columbia that will evaluate genomics in healthcare.
The company trimmed its net loss fell by three-fourths to $11.8 million in the quarter as it continues to rein in costs.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
Clinical sequencing consumables revenues grew 20 percent year over year and accounted for just over 40 percent of total consumables shipments in 2019.
Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.
The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.
In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.
According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.